Health Canada19 Aug 2026
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde may be out of specification in the affected lots.
Health Canada published a recall notice for CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde may be out of specification in the affected lots on 19 Aug 2026. It is one of 311 notices of this kind from Health Canada since 2 Apr 2026 in AreaZine's record.
Recall
The recall notice
- Issued by
- Health Canada
- Issued
- 19 Aug 2026
- Recall type
- Health product recall
- Companies
- Juno Pharma Canada Inc.(Omega Laboratories Limited)11177 Rue Hamon, Montreal, QC, Canada H3M 3E4
- Official source
- Health Canada: the notice at its source
The latest from Health CanadaEvery warning and recall in Canada
Source: Health Canada: the notice at its source. AreaZine rebuilds this page from the agency's record; the agency's page is the one to act on. Contains information licensed under the Open Government Licence – Canada.
The notice as issued
Issue: The level of the degradation product Benzaldehyde may be out of specification in the affected lots. What you should do What to do: Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall. Report any health product related side effects to Health Canada. Report any other health product safety complaints to Health Canada. Additional information Background Affected products: Brand Product Name Market Authorization Dosage Form Strength Lot Number Omega Laboratories Limited Cisatracurium Besylate Injection USP Multidose DIN 02408813 Solution Cisatracurium (Cisatracurium besilate) 2 mg/mL B5C646A, B5D664A Issue
Source: Health Canada: the notice at its source. The text is the agency's, unedited. Contains information licensed under the Open Government Licence – Canada.